The End of Alzheimer’s? A revolutionary scientific advance to the cure

Interface Dynamics Control Corporation (IDCC) has completed the first phase of its decade-long Advanced Therapeutic Interventions Project, with the result that a new approach to arresting and curing Alzheimer’s disease and the other neurodegenerative diseases has been produced and verified. IDCC is now launching the Project’s second phase, which will validate the first phase findings.

Alzheimer’s disease is the sixth leading cause of death in the United States, with more than 5.1 million Americans currently affected. The direct cost of Alzheimer’s is greater than $200 billion annually, a number expected reach between $1.2 and $1.5 trillion by 2050. Indirect costs are substantial: more than 15 million caregivers delivered some 17.5 billion hours of unpaid care valued at more than $200 billion.

IDCC has discovered the mechanism of and means to control the protein misfolding, abnormal aggregation, and degradation processes associated with the degenerative and prion diseases. That mechanism is also implicated in the failure to clear toxic intracellular proteins and in the dysfunction of apoptotic (programmed cell death) pathways. It underlies the adverse functions of the neuroglia (glial cells), including microglia, which provide immune defense to the central nervous system (CNS) and maintain homeostasis and protection for neurons in the brain and the peripheral nervous system.

The process of neurodegeneration has not been understood previously, which has precluded the production of any arresting or curative procedures or drugs. The Project’s findings, however, should lead to the realization of a new class of curative procedures and pharmaceuticals which can be engaged to defeat the disease-initiating neurodegenerative insult, thereby introducing the possibility of preventing these devastating diseases. There are direct implications for the human cancers, but verification of those implications must await further experiments.

The first major activity under the Project’s second phase will be the production of a new class of active imaging system. That system will be utilized to demonstrate the activities and accessible control points of the process pathways which, when certain abnormal events occur, trigger the incipient causal mechanisms of disease. The Project is currently developing the staff and capitalization required for execution of its second phase.

About IDCC 
IDCC was founded thirteen years ago to produce definitive solutions to seemingly intractable problems of social and technological significance. It is privately held and maintains its projects and client identities in strict confidence unless and until information releases are authorized by competent authority.

Contact Details: Peter W. Atkinson
4655 Logsdon Drive
Annandale, VA 22003-3564 USA

Via EPR Network
More Healthcare press releases